SPECIAL REPORT: TREATMENT RESISTANCE
Schizophrenia impacts about 1% of the inhabitants and causes an incredible burden on sufferers and households.1 Sufferers with schizophrenia current with numerous signs (ie, optimistic, destructive, and cognitive), and the course and response to remedy varies extensively. The idea of this heterogeneity is unknown however presumably outcomes from a posh interplay of a number of genetic and environmental components. To determine extra homogeneous subpopulations, efforts have been made to make use of subtype primarily based on medical presentation or response to remedy, or by biomarkers derived from imaging, omics, or postmortem pathology (Figure). As a result of heterogeneity, subtyping approaches maintain promise and must be thought of when designing research.
Definition of Response Subtypes
About 70% of sufferers reply a minimum of fairly effectively to remedy with normal antipsychotics (plus psychosocial interventions), and therefore are thought of to have non–treatment-resistant schizophrenia (non-TRS). Nonetheless, as much as 30% of sufferers don’t reply to straightforward antipsychotic remedy and are due to this fact thought of to have TRS, usually outlined as a failed response to 2 full trials of typical antipsychotics (see Remedy Response and Resistance in Psychosis [TRRIP] tips2 for extra particulars). The one US Meals and Drug Administration (FDA)-approved drugs for TRS is clozapine3; nevertheless, about 30% of TRS sufferers don’t reply to clozapine and are thought of to have ultra-TRS (UTRS).4 At present, these definitions refer primarily to enchancment in optimistic signs, reflecting the larger efficacy of obtainable antipsychotics for treating optimistic signs in comparison with destructive and cognitive signs. TRS (grouped along with UTRS in most research) might derive from a extra extreme model of the identical underlying pathophysiology as non-TRS. Nonetheless, it’s doable that TRS could also be a definite subtype of the sickness with a distinct pathophysiology than non-TRS.5,6
Scientific Options
Evaluation of medical phenotype means that sufferers with TRS have an earlier age of onset than sufferers with non-TRS.7,8 Not like non-TRS, the ratio of males to girls with TRS is equal,7,8 though the extent to which this displays a organic distinction between non-TRS and TRS relatively than the interplay of gender roles and age of illness onset stays to be decided. On the time of first analysis, sufferers who finally develop TRS are extra doubtless than future non-TRS sufferers to be inpatients, to require extra drugs, and to spend greater than 30 days in a psychiatric hospital.8 Cognitive functioning, and significantly verbal memory, is extra impaired in sufferers with TRS than with non-TRS.9,10 TRS can also be extra familial than non-TRS; first- and second-degree family of sufferers with TRS have an elevated threat of creating schizophrenia in contrast with family of sufferers with non-TRS.11 The extent to which optimistic, destructive, and cognitive signs affiliate with this completely different sample of inheritance stays unclear.
Neurobiological Options
To know the neurobiology of TRS, investigations have taken 2 common approaches. One is to find out the genetics of clozapine response, and the second is to determine genes and organic pathways most related to TRS. Preliminary pharmacogenetic research of clozapine took a candidate gene method and tended to deal with the foremost neurotransmitter techniques implicated within the pharmacodynamics of clozapine and different antipsychotics. Response to clozapine was preliminarily related to genetic markers linked to dopamine and serotonin receptors.12 Nonetheless, these findings haven’t been persistently replicated, presumably on account of variation within the standards used to pick topics, inconsistencies within the definition of TRS, and ethnic variations among the many populations underneath investigation, all within the context of small impact sizes.
Unbiased, noncandidate approaches to the neurobiology of schizophrenia present a possibility to determine novel pathogenic pathways. As a result of creating new antipsychotics primarily based on fine-tuning the neurotransmitter profile of beforehand developed antipsychotics has not led to marked breakthroughs in medical efficacy, this new method is of crucial significance. That is mirrored in more moderen pharmacogenomic approaches, utilizing genome-wide affiliation research (GWAS) as a substitute of knowledge restricted to markers related to prespecified candidate genes. Findings recommend that sufferers with TRS, in contrast with sufferers with non-TRS, have greater polygenetic threat scores (an index of general genetic threat of creating a illness),13 a better frequency of disruptive mutations,14 and better charges of chromosomal duplications and deletions.15 This method has discovered an affiliation between particular genomic loci and TRS together with inter-alpha-trypsin inhibitor heavy chain 3/4 (ITIH3/4); calcium voltage-gated channel subunit alpha1 C (CACNA1C); and serologically outlined colon most cancers antigen 8 (SDCCAG8).16 Many of those research haven’t but been replicated, once more doubtless a consequence small pattern measurement, inconsistent inclusion standards, and ranging definitions of TRS.
In its place method to pharmacogenomic research of clozapine utilizing GWAS, our laboratory examined gene expression in autopsied human brains from people with TRS (on clozapine at time of dying) and non-TRS (on typical antipsychotics at time of dying).17 Various particular genes had been in a different way expressed, together with the genes glutamate-cysteine ligase modifier subunit (GCLM), zinc finger protein 652 (ZNF652), and glycophorin C (GYPC). Pathways related to TRS included clathrin-mediated endocytosis, stress-activated protein kinase/c-Jun-terminal kinase signaling, 3-phosphoinositide synthesis, and paxillin signaling, every offering potential leads within the seek for new therapeutic targets.
Imaging Options
Imaging research present relative frontal and temporal gray matter quantity deficits in TRS,18-21 doable white matter tract disruption,22 and disruptions of purposeful connectivity, significantly in frontotemporal networks, with direct and oblique involvement of the thalamus.23-25 Perfusion measured by single-photon emission computerized tomography (SPECT) seems to be decreased in a number of mind areas in TRS and is partially corrected by clozapine; medical enchancment correlates with improved perfusion within the thalamus.18,26,27
Additional, treatment-resistant hallucinations correlated with elevated cerebral blood movement measured by arterial spin label MRI within the temporal-parietal cortex.28 (18)F-FDOPA positron emission tomography research detected greater striatal DA synthesis capability in sufferers with non-TRS than in these with TRS and wholesome management (HC) people, however no distinction in DA synthesis capability between TRS and HC.29 Elevated glutamate focus within the anterior cingulate cortex was recognized within the sufferers with TRS in contrast with non-TRS and HC,30 a discovering that was subsequently replicated.31 The utility of those measures for figuring out which sufferers ought to obtain clozapine stays to be decided.
Differentiating UTRS and TRS
To this point, few research separate TRS from UTRS, which is probably a severe obstacle to defining illness neurobiology, as these 2 types of TRS could also be pathologically and pathophysiologically distinct. The findings of the few research which have straight in contrast TRS with UTRS, or UTRS with HC, are listed in Table 1. It’s doubtless that these are basic to the sickness and never an element of illness development as a result of the vast majority of sufferers who develop TRS accomplish that from the onset of signs,39 and the vast majority of sufferers with UTRS present restricted enchancment from the start of remedy with clozapine. To this point, these findings stay preliminary and await replication. Utilizing biochemical methods, our laboratory has not too long ago demonstrated elevated protein insolubility, and probably protein aggregation, in a subset of autopsied brains of people with schizophrenia.40 It’s doable that this phenomenon, or associated pathophysiological processes, might distinguish amongst non-TRS, TRS, and UTRS.
We carried out a cross-sectional research to find out if there are variations in signs, cognitive functioning, or real-world purposeful capability that distinguish UTRS from TRS.41 Sufferers who responded to clozapine carried out considerably higher on a validated evaluation software of perform, developed by Philip Harvey, PhD, and colleagues, consisting of laptop simulations of banking at an ATM, buying a ticket, and acquiring a prescription refill, and on general cognition as assessed by the Transient Evaluation of Cognition in Schizophrenia. The cross-sectional design didn’t permit us to find out if sufferers who finally responded to clozapine had been as impaired as eventual nonresponders however improved on clozapine, or in the event that they had been much less functionally impaired on the outset of clozapine remedy. This final query will probably be addressed in a longitudinal research of people starting remedy with clozapine.
This research highlights the potential confounding of grouping UTRS with TRS in research of illness phenotype, pathogenesis, and remedy response. It’s doable, as an example, that some—or all—of the genetic and neurobiological variations reported between non-TRS and TRS is actually pushed by UTRS. Moreover, our work on protein homeostasis abnormalities and protein insolubility means that pathological processes may be recognized in a subtype of sufferers with medical correlations subsequently decided and finally, particular therapies designed (Figure).40 Taken collectively, the obtainable information means that subtyping primarily based on remedy response is a believable method to understanding the heterogenous pathophysiological mechanisms associated to schizophrenia. That is considerably analogous to the previous recognition that subtypes of psychotic syndromes that strongly resemble idiopathic schizophrenia may very well be defined by infections (eg, syphilis), dietary deficiency (eg, niacin), or substances (eg, power amphetamine abuse).
Traditionally, the sort of reasoning has led to advances and particular therapies, as particular causes of psychotic syndromes—together with syphilis, niacin deficiency, and power amphetamine abuse—had been recognized. TRS is one solution to subtype sufferers, however different approaches utilizing variability in physiological parameters, such because the Bipolar and Schizophrenia Community for Intermediate Phenotypes (BSNIP), or protein homeostats abnormalities, as we have now proven, are different ways in which this downside may very well be addressed.
Suggestions for Remedy
Though clozapine has been clearly established because the remedy of alternative for people with schizophrenia who don’t reply to 2 trials of a typical antipsychotic, or who produce other particular indications, it’s vastly underused. Based mostly on the speed of remedy failure of typical antipsychotics, the indication of clozapine for lowering the danger of suicide, the comparatively low threat of neurological issues with clozapine, and the potential worth of the drug in ameliorating schizophrenia signs akin to polydipsia, between 30% and 40% of US sufferers with schizophrenia must be receiving clozapine, whereas the precise fee is roughly 4%.42 Even for these receiving clozapine, the typical delay from the time limit when clozapine would have been thought of indicated is 48 months.43 Sufferers who may reply to clozapine are as a substitute handled with a number of antipsychotics or high-dose antipsychotics. The underuse is probably going a consequence of strict tips for prescribing clozapine that burden each clinicians and sufferers, and concern of adversarial results on the a part of affected person, household, and clinicians.
Sadly, our present understanding of the neurobiology of TRS and UTRS is inadequate to foretell who will reply to clozapine and who will develop adversarial results. Delay in initiating clozapine remedy is related to poorer outcomes, and probably with adversarial results from publicity to extra doses of ineffective medicines. Clozapine adversarial results may be monitored and mitigated, and information recommend that sufferers are much less bothered by necessary blood attracts than prescribers are likely to suppose and like clozapine to different medicines.44-46
There are a variety of assets to assist prescribers wishing to make use of clozapine (Table 2). Increasing these applications and looking for recommendation from established clozapine clinics, such because the one we have now at Johns Hopkins, and others throughout the nation might present instruction and session. Enhancing the convenience of use of the agent and enjoyable among the Clozapine Danger Analysis and Mitigation Technique registry restrictions might assist tackle the underutilization of clozapine.
Concluding Ideas
These information recommend that subtyping sufferers primarily based on remedy response (TRS or UTRS versus non-TRS) might determine extra homogeneous populations of sufferers with distinct variations in pathophysiology. Understanding the mechanisms resulting in TRS and UTRS, and the distinction between the two, might present the chance to develop biomarkers of illness state and remedy response, and to develop novel therapies. Additional, the obtainable information means that genetic, medical, and pathogenic research will profit by contemplating remedy response as a variable. Lastly, sufferers with schizophrenia who don’t reply effectively to remedy endure significantly and place nice stress on their households and the well being care system. Funding in analysis and companies for this group of sufferers is crucial.
Dr Nucifora is an affiliate professor of psychiatry and behavioral sciences at Johns Hopkins College College of Medication in Baltimore, Maryland.
References
1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
2. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216-229.
3. Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14(3):750-761.
4. Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017;62(11):772-777.
5. Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry. 2017;17(1):12.
6. Nucifora FC Jr, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257.
7. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Findling RL, Thompson PA. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry. 1997;154(4):475-482.
8. Wimberley T, Støvring H, Sørensen HJ, et al. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry. 2016;3(4):358-366. Printed correction seems in Lancet Psychiatry. 2016;3(4):320.
9. Joober R, Rouleau GA, Lal S, et al. Neuropsychological impairments in neuroleptic-responder vs -nonresponder schizophrenic patients and healthy volunteers. Schizophr Res. 2002;53(3):229-238.
10. de Bartolomeis A, Balletta R, Giordano S, et al. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. 2013;210(2):387-395.
11. Joober R, Rouleau GA, Lal S, et al. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients. Schizophr Res. 2005;77(1):35-41.
12. Sriretnakumar V, Huang E, Müller DJ. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. Professional Opin Drug Metab Toxicol. 2015;11(11):1709-1731.
13. Frank J, Lang M, Witt SH, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol Psychiatry. 2015;20(7):913.
14. Ruderfer DM, Charney AW, Readhead B, Kidd BA. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry. 2016;3(4):350-357.
15. Martin AK, Mowry B. Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia. Psychol Med. 2016;46(3):469-476.
16. Hamshere ML, Walters JT, Smith R, et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol Psychiatry. 2013;18(6):708-712. Printed correction seems in Mol Psychiatry. 2013;18(6):738.
17. Lee BJ, Marchionni L, Andrews CE, et al. Analysis of differential gene expression mediated by clozapine in human postmortem brains. Schizophr Res. 2017;185:58-66.
18. Molina V, Tamayo P, Montes C, et al. Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(4):948-954.
19. Anderson VM, Goldstein ME, Kydd RR, Russell BR. Extensive gray matter volume reduction in treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 2015;18(7):pyv016.
20. Quarantelli M, Palladino O, Prinster A, Schiavone V. Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia. Biomed Res Int. 2014;2014:325052.
21. Maller JJ, Daskalakis ZJ, Thomson RH, Daigle M, Barr MS, Fitzgerald PB. Hippocampal volumetrics in treatment-resistant depression and schizophrenia: the devil’s in de-tail. Hippocampus. 2012;22(1):9-16.
22. Holleran L, Ahmed M, Anderson-Schmidt H, et al. Altered interhemispheric and temporal lobe white matter microstructural organization in severe chronic schizophrenia. Neuropsychopharmacology. 2014;39(4):944-954.
23. Wolf ND, Sambataro F, Vasic N, et al. Dysconnectivity of multiple resting-state networks in patients with schizophrenia who have persistent auditory verbal hallucinations. J Psychiatry Neurosci. 2011;36(6):366-374.
24. Vercammen A, Knegtering H, den Boer JA, Liemburg EJ, Aleman A. Auditory hallucinations in schizophrenia are associated with reduced functional connectivity of the temporo-parietal area. Biol Psychiatry. 2010;67(10):912-918.
25. Alonso-Solís A, Vives-Gilabert Y, Grasa E, et al. Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations. Schizophr Res. 2015;161(2-3):261-268.
26. Molina Rodríguez V, Montz Andrée R, Pérez Castejón MJ, et al. Cerebral perfusion correlates of negative symptomatology and parkinsonism in a sample of treatment-refractory schizophrenics: an exploratory 99mTc-HMPAO SPET study. Schizophr Res. 1997;25(1):11-20.
27. Molina V, Gispert JD, Reig S, et al. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology (Berl). 2005;178(1):17-26.
28. Wolf ND, Grön G, Sambataro F, et al. Magnetic resonance perfusion imaging of auditory verbal hallucinations in patients with schizophrenia. Schizophr Res. 2012;134(2-3):285-287.
29. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169(11):1203-1210.
30. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75(5):e11-e13.
31. Mouchlianitis E, Bloomfield MAP, Regulation V, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. 2016;42(3):744-752.
32. Griffiths Ok, Millgate E, Egerton A, MacCabe JH. Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. Psychol Med. 2021;51(3):376-386.
33. Molina Rodríguez V, Montz Andreé R, Pérez Castejón MJ, et al. SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. Am J Psychiatry. 1996;153(10):1343-1346.
34. Goldstein ME, Anderson VM, Pillai A, et al. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol. 2015;18(6):pyu117.
35. Iwata Y, Nakajima S, Plitman E, et al. Glutamatergic neurometabolite levels in patients with ultra-treatment-resistant schizophrenia: a cross-sectional 3T proton magnetic resonance spectroscopy study. Biol Psychiatry. 2019;85(7):596-605.
36. McNabb CB, Tait RJ, McIlwain ME, et al. Functional network dysconnectivity as a biomarker of treatment resistance in schizophrenia. Schizophr Res. 2018;195:160-167.
37. Fond G, Godin O, Boyer L, et al; FACE-SZ (FondaMental Tutorial Facilities of Experience for Schizophrenia) Group. Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort. Eur Arch Psychiatry Clin Neurosci. 2019;269(8):985-992.
38. Kim J, Plitman E, Iwata Y, et al. Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109839.
39. Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47:1981-1989.
40. Nucifora LG, MacDonald ML, Lee BJ, et al. Increased protein insolubility in brains from a subset of patients with schizophrenia. Am J Psychiatry. 2019;176(9):730-743.
41. Nucifora FC Jr, Baker KK, Stricklin A, et al. Better functional capacity and cognitive performance in clozapine responders compared to non-responders: a cross-sectional study. Schizophr Res. 2021;229:134-136.
42. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012;6(3):134-144.
43. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481-485.
44. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24(7):965-971.
45. Hodge Ok, Jespersen S. Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians. Int J Ment Well being Nurs. 2008;17(1):2-8.
46. Taylor DM, Shapland L, Laverick G, Bond J, Munro J. Clozapine – a survey of affected person perceptions. Psychiatr Bull. 2000;24(12):450-452. ❒
